Neogene Therapeutics
Neoantigen-reactive T cell therapy platform for solid tumors
- Sector
- Biotech
- Headquarters
- New York, NY
- Founded
- 2018
- Latest Form D
- $110M, Sep 2020
- Total capital
- $125M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $125M
- 2 Form D · last Sep 2020
- 73 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 21 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$110M
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Antonius N.M. SchumacherDirectorNamed in SEC Form D filings
- Caroline N.M. StoutDirectorNamed in SEC Form D filings
- Carsten Linnemann, PhDExecutive Officer, Director, PromoterNamed in SEC Form D filings
- David M. TanenDirector, PromoterNamed in SEC Form D filings
- Elisa N.M. PetrisDirectorNamed in SEC Form D filings
- Fei M. ChenDirectorNamed in SEC Form D filings
Show all 11 people
- Franz N.M. HumerDirectorNamed in SEC Form D filings
- Helen M. KimDirectorNamed in SEC Form D filings
- Katherine WoodDirectorNamed in SEC Form D filings
- Rachel N.M. MearsDirectorNamed in SEC Form D filings
- Rajul JainDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 22- GrantedMethods To Enrich Genetically Engineered T CellsUSPTOUS 12,492,386
- PendingEngineered T Cells With Reduced Tgf-beta Receptor SignalingUSPTOApplication 18055370
- PendingEngineered Antigen Presenting CellsUSPTOApplication 17578955
Show all 22 patent records
- Methods To Enrich Genetically Engineered T CellsDec 9, 2025 · US 12,492,386Granted
- Engineered T Cells With Reduced Tgf-beta Receptor SignalingNov 23, 2023 · Application 18055370Pending
- Engineered Antigen Presenting CellsJul 21, 2022 · Application 17578955Pending
- Peptide Markers To Track Genetically Engineered CellsJun 23, 2022 · Application 17557514Pending
- Method To Isolate Tcr GenesFeb 11, 2021 · Application 16927661Pending
- Methods To Enrich Genetically Engineered T CellsApplication 63221808Pending
- Methods To Enrich Genetically Engineered T CellsApplication 63170269Pending
- Peptide Markers To Track Genetically Engineered CellsApplication 63170196Pending
- Engineered Antigen Presenting CellsApplication 63139680Pending
- Methods To Enrich Genetically Engineered T CellsApplication 63135460Pending
- Peptide Markers To Track Genetically Engineered CellsApplication 63129480Pending
- Methods to enrich genetically engineered T cellsApplication 63062854Pending
- Method To Isolate Tcr GenesApplication PCTUS2020041824Pending
- Method To Isolate Tcr GenesApplication 63039346Pending
- Method To Isolate Tcr GenesApplication 63034157Pending
- Method To Isolate Tcr GenesApplication 63024341Pending
- Method To Isolate Tcr GenesApplication 62975924Pending
- Method To Isolate Tcr GenesApplication 62874125Pending
- Engineered T Cells With Reduced Tgf-beta Receptor SignalingApplication 63337091Pending
- Engineered Antigen Presenting CellsApplication PCTUS2022012935Pending
- Peptide Markers To Track Genetically Engineered CellsApplication PCTUS2021073057Pending
- Engineered T Cells With Reduced Tgf-beta Receptor SignalingApplication 63279551Pending
Related companies, and why
- BIOMEDIT LLCSimilar federal contract value in Biotech · null in contracts
- ELGIA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- WHITE ROCK THERAPEUTICSSimilar federal contract value in Biotech · null in contracts
- VBI VACCINES INC.Similar federal contract value in Biotech · null in contracts
- ROTATION MEDICAL INCSimilar federal contract value in Biotech · null in contracts
- KINETA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .